Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
HALO or AXSM: Which Is the Better Value Stock Right Now?
12:40pm, Friday, 09'th Jan 2026
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Axsome Therapeutics (AXSM). But which of these two stocks offers va
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
08:23am, Thursday, 08'th Jan 2026
Biotech companies provide the medical innovations and technological breakthroughs that improve healthcare and can achieve tremendous financial results in the process. However, these names also tend to
2 Healthcare Stocks to Buy for 2026 and Beyond
05:15am, Thursday, 08'th Jan 2026
Axsome Therapeutics and Exelixis are generating solid revenue with their current lineups. Both have promising late-stage candidates that should allow them to expand their portfolios.
Stanley Laman Group Ltd. Makes New $2.13 Million Investment in Axsome Therapeutics, Inc. $AXSM
07:04am, Monday, 05'th Jan 2026
Stanley Laman Group Ltd. acquired a new position in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the third quarter, according to its most recent 13F filing with the SEC. The firm acquired 17,501 sh
Axsome Therapeutics (NASDAQ:AXSM) Director Mark Saad Sells 37,577 Shares
05:17am, Saturday, 03'rd Jan 2026
Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) Director Mark Saad sold 37,577 shares of Axsome Therapeutics stock in a transaction that occurred on Wednesday, December 31st. The stock was
AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation
11:55am, Friday, 02'nd Jan 2026
Axsome stock jumps as the FDA grants priority review to sNDA for AXS-05 in Alzheimer's agitation, with a decision expected April 30, 2026.
Axsome (AXSM) Stock Jumps 22.8%: Will It Continue to Soar?
09:30am, Friday, 02'nd Jan 2026
Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Axsome Therapeutics Stock Jumps After FDA Grants Priority Review For Alzheimer's Agitation Drug
12:17pm, Wednesday, 31'st Dec 2025
Axsome stock jumped Wednesday after the biotech firm said its Alzheimer's disease agitation drug will get a priority review.
Axsome Therapeutics Gains on FDA Priority Review for Alzheimer's Treatment
12:14pm, Wednesday, 31'st Dec 2025
Axsome Therapeutics (AXSM) saw its stock surge after the FDA accepted its supplemental New Drug Application (sNDA) for AXS-05 in treating agitation in Alzheimer
Why Axsome Therapeutics Stock Rocketed Higher to End 2025
12:12pm, Wednesday, 31'st Dec 2025
Axsome just received priority review designation for its most important drug. Auvelity is an oral medication already approved for adults with major depressive disorder (MDD).
Pharma Stock Soars to Record Highs on FDA Buzz
11:32am, Wednesday, 31'st Dec 2025
Pharma stock Axsome Therapeutics Inc (NASDAQ:AXSM) is soaring to all-time highs, up 19% at $177.13 at last glance, after the U.S. Food & Drug Administration (FDA) granted priority review to AXS-05 --
FDA Fast-Tracks Axsome's Alzheimer's Agitation Drug, Stock Soars
10:30am, Wednesday, 31'st Dec 2025
On Wednesday, the U.S. Food and Drug Administration (FDA) accepted Axsome Therapeutics Inc.'s (NASDAQ: AXSM) supplemental New Drug Application (NDA) for AXS-05 (dextromethorphan HBr and bupropion HCl)
Market Movers: Nike Exploding Higher on Insider Buying
10:08am, Wednesday, 31'st Dec 2025
Oversold shares of Nike (NYSE: NKE) are on the run. All on news that CEO Elliott Hill bought 16,400 shares for about $1 million. This follows news that Apple's Tim Cook bought $3 million worth of Nike
FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutica
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
06:55am, Wednesday, 31'st Dec 2025
New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in t
